374 related articles for article (PubMed ID: 17332285)
21. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
22. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
23. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
24. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
25. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.
Möllemann M; Wolter M; Felsberg J; Collins VP; Reifenberger G
Int J Cancer; 2005 Jan; 113(3):379-85. PubMed ID: 15455350
[TBL] [Abstract][Full Text] [Related]
26. Molecular profile of oligodendrogliomas in young patients.
Suri V; Jha P; Agarwal S; Pathak P; Sharma MC; Sharma V; Shukla S; Somasundaram K; Mahapatra AK; Kale SS; Sarkar C
Neuro Oncol; 2011 Oct; 13(10):1099-106. PubMed ID: 21937591
[TBL] [Abstract][Full Text] [Related]
27. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
[TBL] [Abstract][Full Text] [Related]
28. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L
Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900
[TBL] [Abstract][Full Text] [Related]
30. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D
Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790
[TBL] [Abstract][Full Text] [Related]
31. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
[TBL] [Abstract][Full Text] [Related]
32. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.
Molinari C; Iorio P; Medri L; Ballardini M; Guiducci G; Cremonini AM; Cerasoli S; Riccioni L; Faedi M; Mariani GA; Zoli W; Silvestrini R; Calistri D
Int J Mol Med; 2010 Jan; 25(1):145-51. PubMed ID: 19956913
[TBL] [Abstract][Full Text] [Related]
34. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
Kim SH; Kim H; Kim TS
Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
[TBL] [Abstract][Full Text] [Related]
35. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity.
Walker C; du Plessis DG; Joyce KA; Machell Y; Thomson-Hehir J; Al Haddad SA; Broome JC; Warnke PC
Clin Cancer Res; 2003 Oct; 9(13):4841-51. PubMed ID: 14581356
[TBL] [Abstract][Full Text] [Related]
36. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
Choi KY; Jung TY; Jung S; Kim YH; Moon KS; Kim IY; Kang SS; Lee KH
J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
[TBL] [Abstract][Full Text] [Related]
39. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C
Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176
[TBL] [Abstract][Full Text] [Related]
40. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
